Exact Sciences

Jul 1, 2022

In Brief This Week: CAP, CDC, Exact Sciences, Grail, More

Jun 30, 2022

PreventionGenetics Nabs FDA Approval for Obesity Drug Companion Diagnostic

Jun 21, 2022

Ultima Genomics, Exact Sciences Ink Long-Term Sequencing Supply Agreement

Jun 14, 2022

Exact Sciences Bolsters Plasma Proteomics Tech With $15M Purchase of OmicEra
Premium

May 9, 2022

Guardant Health Confident in New CRC Screening Blood Test Despite Competitor Skepticism
Premium

Apr 28, 2022

As Competing Blood-Based Cancer Screening Tests Loom, Exact Sciences Stresses Cologuard Advantage
Premium

Apr 26, 2022

Exact Sciences Q1 Revenues up 21 Percent

Apr 13, 2022

Guardant Health, Exact Sciences Make Progress on Multi-Cancer Detection Tests
Premium

Feb 22, 2022

Exact Sciences Q4 Revenues up 2 Percent; Non-COVID-19 Revenues Rise 16 Percent

Feb 17, 2022

Mainz Biomed Developing New Version of ColoAlert Assay Ahead of FDA Submission
Premium

Jan 13, 2022

JP Morgan Healthcare Conference Day 3: Quest Diagnostics, Exact Sciences, Quidel, More

Jan 10, 2022

Exact Sciences Projects up to $475M in Q4 Revenues, Acquires Testing Lab, Inks Licensing Deal

Nov 30, 2021

Exact Sciences, Pfizer End Cologuard Copromotion Agreement

Nov 18, 2021

Exact Sciences, Jefferson Health to Study Blood-Based Multicancer Early Detection Test

Nov 3, 2021

Exact Sciences Gearing up for Busy 2022, Beyond
Premium

Nov 2, 2021

Exact Sciences Q3 Revenues Rise 12 Percent

Sep 15, 2021

Exact Sciences Stock Spikes After Primary Care Sales Team Nearly Doubles

Sep 14, 2021

Exact Sciences, NSABP Validating Ability of ctDNA Test to Detect MRD in Colorectal Cancer Patients

Aug 16, 2021

Exact Sciences' Oncotype DX Breast Recurrence Score Assay Receives Japanese Regulatory Approval

Jul 28, 2021

Exact Sciences Q2 Revenues Rise 62 Percent